Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9)

Tadahiko Igarashi, Michinori Ogura, Kuniaki Itoh, Masafumi Taniwaki, Kiyoshi Ando, Yoshiaki Kuroda, Kazuhito Yamamoto, Naokuni Uike, Akihiro Tomita, Hirokazu Nagai, Mitsutoshi Kurosawa, Shigeo Mori, Shigeru Nawano, Takashi Terauchi, Yasuo Ohashi, Kensei Tobinai

Research output: Contribution to journalComment/debate

Abstract

The authors would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The Clinical trial number should be “UMIN000001603” at the end of Abstract and in the last sentence of the paragraph heading “Study design and patients” under “Materials and methods” section. Secondly, the Fig. 1 was incorrectly published with the meaningless red font. The corrected figure is given below: (Figure presented.).

Original languageEnglish
Pages (from-to)109-110
Number of pages2
JournalInternational Journal of Hematology
Volume105
Issue number1
DOIs
Publication statusPublished - 01-01-2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Igarashi, T., Ogura, M., Itoh, K., Taniwaki, M., Ando, K., Kuroda, Y., Yamamoto, K., Uike, N., Tomita, A., Nagai, H., Kurosawa, M., Mori, S., Nawano, S., Terauchi, T., Ohashi, Y., & Tobinai, K. (2017). Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden (International Journal of Hematology, (2016), 104, 6, (700-708), 10.1007/s12185-016-2097-9). International Journal of Hematology, 105(1), 109-110. https://doi.org/10.1007/s12185-016-2155-3